ESC 365 - Welcome: The shifting risk/benefit balance of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation and cardiac interventions.

Open Access

Welcome: The shifting risk/benefit balance of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation and cardiac interventions.

Session: Optimising oral anticoagulation for atrial fibrillation patients undergoing cardiac interventions in 2021: From evidence to practice

Topic: Atrial Fibrillation (AF)

Speaker: Professor I. Van Gelder (Groningen, NL)

Sponsored by Bristol Myers Squibb and Pfizer

Event: ESC Congress 2021 - The Digital Experience

Congress Session

About the speaker

Professor Isabelle C Van Gelder

University Medical Center Groningen, Groningen (Netherlands (The))

40 presentations

2 followers

3 more presentations in this session

Building the evidence base for cardiac interventions in non-valvular atrial fibrillation.

Speaker: Professor R. Lopes (Durham, US)

Antithrombotic therapy in patients with transcatheter aortic valve implantation: Balancing risks with benefits.

Speaker: Professor J. ten Berg (Nieuwegein, NL)

Panel Q&A.

Access the full session

Optimising oral anticoagulation for atrial fibrillation patients undergoing cardiac interventions in 2021: From evidence to practice

Speakers: Professor I. Van Gelder, Professor R. Lopes, Professor J. ten Berg

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

Open Access

Hot topics in pacing and implantable cardioverter defibrillator.

5 April 2022

Open Access

Hot topics in ventricular tachycardia.

5 April 2022

Open Access

Hot topics in atrial fibrillation.

5 April 2022

This platform is supported by